THERAPEUTIC ROLE OF FERRITIN IN NEUROBLASTOMA
THERAPEUTIC ROLE OF FERRITIN IN NEUROBLASTOMA
批准号:
3476924
负责人:
JULIE BLATT
金额:
$7.99万
依托单位国家:
美国
项目类别:
财政年份:
1987
资助国家:
美国
项目状态:
已结题
起止时间:
1987-07-01 至 1991-06-30
关键词:
DNA RNA cell population study cellular oncology chelation therapy deferoxamine drug metabolism drug resistance ferritin immunopharmacology immunosuppression neoplasm /cancer chemotherapy neoplasm /cancer classification /staging neoplasm /cancer immunology neoplasm /cancer pharmacology neoplastic growth neuroblastoma nucleic acids pediatric neoplasm /cancer protein biosynthesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Ferritin is an iron-storage protein that is found in normal human
serum. Greater than normal serum levels are found in some
patients with neuroblastoma and predict a poor outcome. Indirect
evidence suggests that ferritin in these patients may be
synthesized by their tumor cells. In an attempt to understand why
ferritin levels correlate with prognosis, studies have focused on
the ability of ferritin to inhibit host immune responses and
thereby enhance tumor growth. It is postulated that in addition to
these effects, ferritin or the ferric ions that it carries may
function as a growth factor for neuroblastoma and directly
contribute to tumor growth. As a correlary it is postulated that
chelation of iron may provide an approach to the treatment of
neuroblastoma. Preliminary data suggest that desferoxamine, a
high affinity iron chelator which can extract iron from ferritin,
kills growing neuroblastoma cells in vitro. To further explore the
biological role of ferritin in neuroblastoma as well as the
mechanism by which desferoxamine kills neuroblastoma cells, it is
proposed: to establish that neuroblastoma cells can synthesize
ferritin; to determine whether ferritin potentiates nucleic acid or
protein synthesis by neuroblastoma cells in serum-free medium;
and to study the ability of neuroblastoma cells to bind ferritin in
the manner of known growth factors. In addition the effect of
desferoxamine on tumor cell lines with respect to DNA, RNA and
protein synthesis, cell cycling, and activity of iron-dependent
cellular enzymes will be studied. Finally, utilizing available
toxicity data, a phase II clinical trial of desferoxamine in children
with end-stage neuroblastoma and other malignancies will be
conducted.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
--
发表时间:
1989-06
期刊:
Cancer research
影响因子:
11.2
作者:
[J. Blatt;S. Taylor;G. Kontoghiorghes]
通讯作者:
J. Blatt;S. Taylor;G. Kontoghiorghes
DOI:
--
发表时间:
1988-10
期刊:
The Journal of laboratory and clinical medicine
影响因子:
--
作者:
[J. Blatt;S. Taylor;S. Stitely]
通讯作者:
J. Blatt;S. Taylor;S. Stitely
Synthesis of ferritin by neuroblastoma.
神经母细胞瘤合成铁蛋白。
DOI:
--
发表时间:
1990
期刊:
Cancer biochemistry biophysics
影响因子:
--
作者:
[Blatt,J, Huntley,D, Eagon,PK]
通讯作者:
Eagon,PK
Stimulation of growth of neuroblastoma cells by ferritin in vitro.
体外铁蛋白刺激神经母细胞瘤细胞的生长。
DOI:
--
发表时间:
1992
期刊:
The Journal of laboratory and clinical medicine
影响因子:
--
作者:
[Blatt,J, Wharton,V]
通讯作者:
Wharton,V
STUDY OF SELECTED LATE EFFECTS IN PATIENTS TREATED FOR NONHODGKINS LYMPHOMA
-
批准号:6246639
-
项目类别:
-
资助金额:$1.91万
-
财政年份:1996
-
负责人:JULIE BLATT
-
依托单位:
PEDIATRIC PHASE I TRIAL AND PHARMACOKINETIC STUDY OF LGC1057
-
批准号:6246652
-
项目类别:
-
资助金额:$1.91万
-
财政年份:1996
-
负责人:JULIE BLATT
-
依托单位:
PHASE I STUDY OF TOPOTECAN AND CISPLATIN IN THE TREATMENT OF SOLID TUMORS
-
批准号:6246653
-
项目类别:
-
资助金额:$1.91万
-
财政年份:1996
-
负责人:JULIE BLATT
-
依托单位:
THERAPEUTIC ROLE OF FERRITIN IN NEUROBLASTOMA
-
批准号:3476922
-
项目类别:
-
资助金额:$8.36万
-
财政年份:1987
-
负责人:JULIE BLATT
-
依托单位:
THERAPEUTIC ROLE OF FERRITIN IN NEUROBLASTOMA
-
批准号:3476923
-
项目类别:
-
资助金额:$7.69万
-
财政年份:1987
-
负责人:JULIE BLATT
-
依托单位:
A PHASE I EVALUATION OF TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH MALIGNANCIES
-
批准号:5219311
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JULIE BLATT
-
依托单位:--
PHASE I AND PHASE II EXPERIMENTAL CHEMOTHERAPY STUDIES
-
批准号:3763534
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JULIE BLATT
-
依托单位:
STUDY OF SELECTED LATE EFFECTS IN PATIENTS TREATED FOR NONHODGKINS LYMPHOMA
-
批准号:5219313
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JULIE BLATT
-
依托单位:--
GROWTH FACTORS IN OSTEOGENIC SARCOMA
-
批准号:4700674
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JULIE BLATT
-
依托单位:
PHASE I AND PHASE II EXPERIMENTAL CHEMOTHERAPY STUDIES
-
批准号:3785619
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JULIE BLATT
-
依托单位:
LONG TERM CARDIAC EFFECTS OF DOXORUBICIN AND MEDIASTIAL RADIATION
-
批准号:3849318
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JULIE BLATT
-
依托单位:
PHASE I AND PHARMACOKINETIC STUDY OF TAXOTERE IN CHILDREN - ADVANCED NEOPLASTIC
-
批准号:5219305
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JULIE BLATT
-
依托单位:--
A PHASE 1 STUDY OF TAXOL IN REFRACTORY LEUKEMIA IN CHILDREN
-
批准号:3785617
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JULIE BLATT
-
依托单位:
LONG TERM CARDIAC EFFECTS OF DOXORUBICIN AND MEDIASTINAL RADIATION
-
批准号:3785597
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JULIE BLATT
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于合成生物标志物的超多重RNA数字化检测平台用于肿瘤精准诊断和分期评估
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:程子译
-
依托单位:
RNA m6A修饰通过调控FDX1介导的铜死亡参与补阳还五汤抗脑缺血再灌注损伤作用机制的研究
-
批准号:2026JJ81091
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:刘亮
-
依托单位:
免标记CRISPR-RNA适配体与门逻辑分子诊断新方法研究
-
批准号:2026JJ50010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:应站明
-
依托单位:
Dead-box解旋酶DDX23通过调控RNA高级结构促进肝癌细胞恶性生物学行为的分子机制研究
-
批准号:JCZRLH202600588
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于基因编辑技术解析丹酚酸B靶向SAMHD1调控心肌线粒体RNA稳态干预心衰的分子机制研究
-
批准号:JCZRLH202601084
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
RNA 结合蛋白HuR与VEGF-D联合调控舌鳞癌侵袭及转移机制的研究
-
批准号:2026JJ80684
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:龚攀
-
依托单位:
基于异质人群多源数据识别单细胞 RNA数量性状风险位点的统计学方法研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:蔡铭轩
-
依托单位:
uN2CpolyG蛋白经ALYREF蛋白介导RNA转运异常在神经元核内包涵体病发病中的作用及机制研究
-
批准号:2026JJ60587
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:张思哲
-
依托单位:
病毒非编码RNA多样性图谱构建及其生物发生与致病机制研究
-
批准号:2026JJ60389
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:傅萍
-
依托单位:
核糖核酸酶RNase E与其抑制因子RebA通过液-液相分离调控蓝藻RNA代谢的分子机制
-
批准号:JCZRQNB202600879
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位: